Alnylam Plans Lumasiran Phase III As Market Landscape Gets Competitive

 
• By John Davis
  
Generate a summary of this article
Listen to this article
Beta

Alnylam will take on the global development and commercialization of investigational rare disease therapy lumasiran as Sanofi declines to opt-in to its development, and the US biotech prepares to commercialize its first RNAi therapeutic, pencilled in for later this year.  

Options
Choices have to be made between competing priorities. • Source: Shutterstock

Sanofi's decision not to opt-in to the development and commercialization of ultra-orphan therapy lumasiran is considered a positive for the product's originator, Alnylam Pharmaceuticals Inc., but there are concerns that the French firm has now declined options on several of Alnylam's investigational RNA interference (RNAi) products that might have supported the biotech as it prepares its strategy for the potential approval and launch of lead product, patisiran, for the treatment of hereditary ATTR amyloidosis, in mid-2018.

Alnylam, which now has global rights to lumasiran, has pledged to start Phase III trials with the primary hyperoxaluria type...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Partnered By

Nancy Testing Partnered Content

This is a short description.

Pierre Fabre Pushes To Be Partner Of Choice For Budding Biotechs

 
• By Kevin Grogan

Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.